Apple | Mobile |
---|---|
Business Dev & Design Entertainment | Social Media Tech Web Video |
Apple | Mobile |
---|---|
Business Dev & Design Entertainment | Social Media Tech Web Video |
Develops medical device to treat urinary tract infections.
Year Established: | 2008 |
Funding: | |
Address: | Lexington, MA 02421 |
Telephone: | 2147483647 |
Mobile: | |
Fax: | 781-676-7788 |
Mail: | info@TARISbio.com |
Company URL: | http://www.tarisbiomedical.com |
Careers
TARIS Biomedical an exciting new company located in Lexington Massachusetts is pioneering the emerging field of drug-device convergence for targeted therapies.
TARIS is building a world-class team dedicated to creating innovative new localized therapeutic systems for patients with unmet medical need.
TARIS is an Equal Opportunity Employer and offers a competitive and comprehensive benefits package.
Interested candidates should forward their CV and cover letter with job code to careers@tarisbio.com
TARIS Successfully Completes Phase 1 Study - 12/ 2/09
TARIS Appoints Julie Lekstom Himes MD to CMO post - 11/06/09
TARIS Biomedical Launches with $15 Million in Funding - 6/24/09
PharmaVoice - 10/09
Start Up Magazine - 9/09
Forbes - 7/21/09
Earth Times - 7/21/09
Fierce Biotech - 7/6/09
Medical Device Daily - 6/26/09
Taris Biomedical raises $15 million - Boston Business Journal - 6/25/09
TARIS Biomedical Launches with $15 Million in Funding to Develop Innovative Drug-Device Therapies - REUTERS - 6/24/09
Taris Biomedical Gives Glimpse of Drug-Delivery Tech Discloses $15M Series A Xconomy Ryan McBride - Xconomy Boston - 6/9/09
XSite 2009: XConomy Summit on Innovation Technology and Entrepreneurship - Boston University - 6/24/09
MassMEDICs 11th ANNUAL MEDTECH INVESTORS CONFERENCE - 10/02/09
Boston Biotech R&D Conference - Harvard Medical School - 10/27/09
US-Japan Symposium on Drug Device Systems - Hawaii - 12/16/09
Stay Tuned
Flagship Ventures,Flybridge Capital Partners (FKA: IDG Ventures Boston),Polaris Venture Partners
Michael J. Cima, Ph.D., Founder
Michael J. Cima, Ph.D., is a co-founder and consultant to the TARIS Biomedical management team. Dr. Cima is a Professor of Materials Science and Engineering at the Massachusetts Institute of Technology (MIT) and an investigator at the Koch Institute for Integrative Cancer Research at MIT. Professor Cima is author or co-author of over 190 peer reviewed scientific publications, 45 patents, and is a recognized expert in the field of materials processing. Professor Cima is actively involved in materials and engineered systems aimed at improving human health; such as treatments for cancer, metabolic diseases, trauma, and urological disorders. Professor Cima and collaborators are developing implantable devices for unprecedented control in the delivery of pharmaceuticals. Professor Cima is co-founder and a director of MicroChips Inc. and T2 Biosystems. Most recently, Professor Cima co-founded Entra Pharmaceuticals and TARIS Biomedical. Professor Cima earned a B.S. in chemistry (Phi Beta Kappa) and a Ph.D. in chemical engineering, both from the University of California at Berkeley. Professor joined the MIT faculty in 1986 and was promoted to full Professor in 1995.
back to top
Jessica Anderson, Executive Director, Program Management and Clinical Operations
Jessica Anderson serves as Executive Director, Program Management and Clinical Operations at TARIS Biomedical where she is responsible for program leadership and cross-functional management of key regulatory, formulation, device development, system integration, non-clinical and clinical activities. Prior to joining TARIS, Jessica held senior positions in Program Leadership, Clinical Operations and Analysis, and Data Management and Biostatistics at CombinatoRx from 2005-2008. Jessica has also held clinical management and biostatistics positions at Millennium Pharmaceuticals, Boston Scientific, Amersham and Genzyme Corporation. Jessica earned an M.A. in Statistics and Human Factors at Texas Tech University and a B.S. in Experimental Psychology and Biology at the University of New Mexico.
back to top
Robert Crane, Chief Financial Officer
Mr. Crane serves as Chief Financial Officer at TARIS Biomedical. Mr. Crane has built a business founding, growing and turning around companies in the healthcare field, serving in a variety of roles, principally that of chief financial officer but also has been responsible for manufacturing, clinical and regulatory affairs and other areas as required. Over the last twenty years, Mr. Crane has been involved in nearly 20 companies in a variety of fields including diagnostics, medical devices and therapeutics including I-STAT, Seragen, InKine Pharmaceuticals, Sirtris Pharmaceuticals, Life Medical Sciences, MicroCHIPS and Predictive BioSciences. Earlier in his career, Mr. Crane was a partner at Montgomery Ventures, a prominent San Francisco investment bank. Mr. Crane earned his M.A. in Business Administration from Stanford University and a B.S. in Mechanical Engineering from the Massachusetts Institute of Technology.
back to top
Dennis H. Giesing, Ph.D., Chief Scientific Officer
Dennis Giesing serves as Chief Scientific Officer of Taris Biomedical. Dr. Giesing is also CEO and co-founder of CepheidRx LLC, a pharmaceutical consulting company. Prior to joining TARIS, Dennis served as CSO for Urigen Pharmaceuticals. For over 30 years, Dr. Geisling has served in a variety of senior scientific and leadership roles within large pharmaceutical companies with the last appointment being Senior Vice President, Lead Optimization at Aventis Pharmaceuticals Inc. Earlier Pharma positions include Vice President, Global Drug Metabolism & Pharmacokinetics at Aventis as well as other leadership roles at Hoechst Marion Roussel, Marion Merrell Dow and Marion Laboratories. Dennis earned a B.S. in Chemistry and his Ph.D. in Biochemical Pharmacology at the University of Missouri, Kansas City.
back to top
Cheryl Larrivee-Elkins, Senior Vice President, Product Development and Regulatory Affairs
Cheryl Larrivee-Elkins serves as Senior Vice President of Product Development and Regulatory Affairs at TARIS Biomedical, where her team is responsible for formulation, analytical, process, and device development, regulatory affairs, and quality. Prior to joining TARIS, Cheryl filled several senior leadership roles at Alkermes, Inc., most recently as VP of Regulatory Affairs. Prior to Alkermes, Ms. Elkins was Director, Technical Regulatory Affairs at Sepracor Inc. and held positions of increasing responsibility in pharmaceutical development and technical services during her eight year tenure at AstraZeneca (formerly Astra USA), developing an expertise in parenteral and pulmonary product development, registration, and manufacture. o Cheryl earned her MSChE at the University of Wisconsin-Madison and her BSChE at the Massachusetts Institute of Technology.
back to top
Julie Lekstrom Himes, M.D., Chief Medical Officer and Senior Vice President, Clinical Development.
Dr. Himes serves as Chief Medical Officer and Senior Vice President, Clinical Development at TARIS. Prior to joining TARIS, Dr. Himes was responsible for all clinical programs at Coley Pharmaceuticals, including oncology, chronic hepatitis C and autoimmunity, with direct oversight of clinical operations, outsourcing, data management, drug safety and medical writing functions. As Medical Director for Millennium Pharmaceutical’s Cardiovascular and Inflammation Franchise, Dr. Himes managed the design, execution and regulatory submissions of cardiovascular and anti-inflammatory product candidates. Prior to joining industry, Dr. Himes held academic positions at the National Institutes of Health in the Allergy and Infectious Diseases and Human Genome Research Institutes. Dr. Himes earned her MD at the Medical College of Virginia and her BS in Chemistry at the University of Virginia.